DexCom (DXCM): Cutting PT On Temporary Market Weakness - Wedbush

November 2, 2016 7:59 AM EDT
Get Alerts DXCM Hot Sheet
Price: $64.99 +0.59%

Rating Summary:
    15 Buy, 10 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade DXCM Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Wedbush analyst, Tao Levy, reiterated his Outperform rating on shares of DexCom (NASDAQ: DXCM) but cut the price target to $100 from $112 due to near-term uncertainty that Medtronic’s product launches have created on near-term purchasing patterns of diabetes technology. However, the analyst remains optimistic that growth should improve in 2017.

As mentioned on both Tandem Diabetes (NASDAQ: TNDM) and DexCom’s earnings’ calls, the fourth quarter has started off weaker than expected for the aforementioned reason.

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $77.92 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst PT Change

Related Entities

Earnings, Tao Levy

Add Your Comment